A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM cells by a novel BCMA antibody drug conjugate (ADC) delivering the DNA cross-linking PBD dimer te...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Lijie, Lin, Liang, Yu, Tengteng, Li, Yuyin, Cho, Shih-Feng, Liu, Jiye, Wen, Kenneth, Hsieh, Phillip A, Kinneer, Krista, Munshi, Nikhil, Anderson, Kenneth C, Tai, Yu-Tzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392808/
https://www.ncbi.nlm.nih.gov/pubmed/32060401
http://dx.doi.org/10.1038/s41375-020-0745-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392808/
https://www.ncbi.nlm.nih.gov/pubmed/32060401
http://dx.doi.org/10.1038/s41375-020-0745-9

Ejemplares similares